aTyr Pharma
ATYR
31 hedge funds and large institutions have $9.22M invested in aTyr Pharma in 2018 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 8 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less funds holding
Funds holding: 33 → 31 (-2)
6.58% less ownership
Funds ownership: 44.59% → 38.01% (-6.6%)
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
73% less capital inflows, than outflows
Capital inflows: $697K | Capital outflows: $2.55M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$448K |
| 2 |
Two Sigma Investments
New York
|
+$71.1K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$57K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$50K |
| 5 |
Millennium Management
New York
|
+$25.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Redmile Group
San Francisco,
California
|
-$1.72M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$521K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$114K |
| 4 |
BlackRock
New York
|
-$81K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$35K |
ATYR Hedge Fund Activity: Q3 2018 in Review
31 of the 4,392 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q3 2018, worth a combined $9.22M — down 24% from $12.1M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of ATYR and 6 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 5 added.
The largest buyer was Renaissance Technologies, adding an estimated $448K. The largest seller was Redmile Group, exiting entirely with an estimated $1.72M sold.
- 31 institutional investors held aTyr Pharma (ATYR) as of Q3 2018, down from 33 in Q2 2018.
- Funds reported $9.22M of aTyr Pharma stock for Q3 2018, down 24% quarter-over-quarter.
- 6 funds opened new aTyr Pharma positions in Q3 2018 and 8 closed out, a net change of -2 holders.
- The largest aTyr Pharma buyer in Q3 2018 was Renaissance Technologies, an estimated $448K added.
- The largest aTyr Pharma seller in Q3 2018 was Redmile Group, an estimated $1.72M sold.
Based on aggregated 13F filings for Q3 2018.